NAME,CONCEPT_NAME,CONDR_IDSEQ
C67132,10TH GRADE COMPLETION,371E19EC-E86E-0F0B-E044-0003BA3F9857
C67133,11TH GRADE COMPLETION,371E19EC-E85C-0F0B-E044-0003BA3F9857
C67134,"12TH GRADE COMPLETION, NO DIPLOMA",32BD3337-44E0-3CD6-E044-0003BA3F9857
C13542,16Q,84AD8CAD-BA80-FCC0-E040-BB89AD4326A3
C13382,17P,0D2F7124-4832-8C2F-E050-BB89AD4378C6
C67123,1ST GRADE COMPLETION,371C9548-314F-7422-E044-0003BA3F9857
C67124,2ND GRADE COMPLETION,371C9548-3134-7422-E044-0003BA3F9857
C16035,3-DIMENSIONAL CONFORMAL RADIATION THERAPY,0C625C4B-29A1-27E6-E044-0003BA3F9857
C67125,3RD GRADE COMPLETION,371E19EC-E922-0F0B-E044-0003BA3F9857
C67126,4TH GRADE COMPLETION,371E19EC-E907-0F0B-E044-0003BA3F9857
C13380,5Q,F37D0428-E50A-6787-E034-0003BA3F9857
C67127,5TH GRADE COMPLETION,371E19EC-E8EC-0F0B-E044-0003BA3F9857
C13560,6Q,0D2F7124-472D-8C2F-E050-BB89AD4378C6
C67128,6TH GRADE COMPLETION,371E19EC-E8D1-0F0B-E044-0003BA3F9857
C67129,7TH GRADE COMPLETION,371E19EC-E8B6-0F0B-E044-0003BA3F9857
C92599,8-ISO PROSTAGLANDIN F2ALPHA (8-ISO-PGF2A),A753F5E2-7081-83A5-E040-BB89AD432F35
C13562,8Q,0D2F7124-4985-8C2F-E050-BB89AD4378C6
C67130,8TH GRADE COMPLETION,371E19EC-E89B-0F0B-E044-0003BA3F9857
C67131,9TH GRADE COMPLETION,371E19EC-E880-0F0B-E044-0003BA3F9857
C129349,A FEW TIMES,3E9D5CAE-9D53-5BB3-E053-F662850ADD8F
C91214,A LITTLE BIT,917AA83A-DABB-A8DB-E040-BB89AD43420C
C12664,ABDOMEN,0781A8FE-5085-0C0C-E044-0003BA3F9857
C77333,ABIRATERONE,8C0EAA9F-D690-4F99-E040-BB89AD435CFD
C35221,ABORTION FINDING,4D4AF823-AFDE-5557-E044-0003BA3F9857
C129490,ABOUT EQUALLY SATISFIED AND DISSATISFIED,3E9D5CAE-9E72-5BB3-E053-F662850ADD8F
C3173,"ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE",38DBE882-E45E-674F-E044-0003BA3F9857
C28940,ACETAMINOPHEN-BASED ORAL COUGH AND COLD PREPARATION,0D052842-7279-4FD3-E044-0003BA3F9857
C28807,ACETAMINOPHEN/CODEINE,03E16831-BC6B-6D9B-E044-0003BA3F9857
E12237,ACIDOSIS,8B6C5DD5-D185-4885-E040-BB89AD4353DF
C4022,ACRAL LENTIGINOUS MELANOMA,06CB4BCA-311E-23F2-E044-0003BA3F9857
C4673,ACUTE BIPHENOTYPIC LEUKEMIA,37BE0FBC-A52E-35B4-E044-0003BA3F9857
C8923,ACUTE ERYTHROID LEUKEMIA,F37D0428-DB6E-6787-E034-0003BA3F9857
C3167,ACUTE LYMPHOBLASTIC LEUKEMIA,F37D0428-B5D2-6787-E034-0003BA3F9857
C3170,ACUTE MEGAKARYOBLASTIC LEUKEMIA,F37D0428-DB76-6787-E034-0003BA3F9857
C7318,ACUTE MONOBLASTIC AND MONOCYTIC LEUKEMIA,37BD0487-E0F2-6FAB-E044-0003BA3F9857
C4861,ACUTE MONOCYTIC LEUKEMIA,27F3CBD2-0454-469E-E044-0003BA3F9857
C82427,ACUTE MYELOID LEUKEMIA (MEGAKARYOBLASTIC) WITH T(1;22)(P13.3;Q13.3); RBM15-MKL1,A89D3C60-A1C0-6E25-E040-BB89AD433A3A
C27753,ACUTE MYELOID LEUKEMIA NOT OTHERWISE SPECIFIED,27F3CBD2-04A5-469E-E044-0003BA3F9857
C9018,ACUTE MYELOID LEUKEMIA WITH INV(16)(P13.1Q22); CBFB-MYH11,62470ADA-06F3-83FB-E040-BB89AD436FBF
C3250,ACUTE MYELOID LEUKEMIA WITH MATURATION,F37D0428-DB7E-6787-E034-0003BA3F9857
C8460,ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION,F37D0428-DB86-6787-E034-0003BA3F9857
C9289,ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA,27F3CBD2-03B5-469E-E044-0003BA3F9857
C7600,ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES,37BBBFE3-F0E3-60D3-E044-0003BA3F9857
C9288,ACUTE MYELOID LEUKEMIA WITH T(8;21); (Q22; Q22.1); RUNX1-RUNX1T1,37BBBFE3-F170-60D3-E044-0003BA3F9857
C82403,ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A,E95A151A-B5AA-8777-E040-BB89AD433AA9
C6924,ACUTE MYELOID LEUKEMIA WITH VARIANT MLL TRANSLOCATIONS,F37D0428-DB7A-6787-E034-0003BA3F9857
C3249,ACUTE MYELOID LEUKEMIA WITHOUT MATURATION,F37D0428-DB82-6787-E034-0003BA3F9857
C3182,ACUTE PROMYELOCYTIC LEUKEMIA WITH PML-RARA,F37D0428-B596-6787-E034-0003BA3F9857
C3353,ACUTE RESPIRATORY DISTRESS SYNDROME,F37D0428-CBFA-6787-E034-0003BA3F9857
C4726,ADAMANTINOMATOUS CRANIOPHARYNGIOMA,1222C373-64AE-4AFD-E044-0003BA3F9857
C7683,ADENOCARCINOMA WITH CARTILAGINOUS AND OSSEOUS METAPLASIA,6281C75A-4866-A127-E040-BB89AD431A41
C5130,ADENOID CYSTIC BREAST CARCINOMA,06CB4BCA-315C-23F2-E044-0003BA3F9857
C15675,ADJUVANT THERAPY,F37D0428-E516-6787-E034-0003BA3F9857
LA20739-1,ADOLESCENT (13-17 YEARS),2822FF80-9A75-0EAB-E050-BB89AD4370A6
C3326,ADRENAL GLAND PHEOCHROMOCYTOMA,9F52E161-943C-C614-E040-BB89AD4377D5
C26691,ADRENOCORTICAL INSUFFICIENCY,501F0EC5-3D05-32D2-E044-0003BA3F9857
LA20740-9,ADULT (18-64 YEARS),2822FF80-9A6C-0EAB-E050-BB89AD4370A6
C3184,ADULT T-CELL LEUKEMIA/LYMPHOMA,F37D0428-E66A-6787-E034-0003BA3F9857
C41331,ADVERSE EVENT,F37D0428-B66E-6787-E034-0003BA3F9857
C83052,ADVERSE EVENT ASSOCIATED WITH HOSPITALIZATION,7E1461A5-7A8E-590A-E040-BB89AD436E02
LA20743-3,AGED ADULT (85+ YEARS),2822FF80-9A5E-0EAB-E050-BB89AD4370A6
C8647,AGGRESSIVE NK-CELL LEUKEMIA,F37D0428-E636-6787-E034-0003BA3F9857
E12242,ALCOHOL INTOLERANCE,8AA8E6AF-FD0C-E859-E040-BB89AD433043
C1574,ALITRETINOIN,05116195-EB70-7341-E044-0003BA3F9857
C27032,ALK TYROSINE KINASE RECEPTOR,822BAC66-A5A4-B260-E040-BB89AD432869
E12082,ALKALINE PHOSPHATASE INCREASED,8AA8E6AF-FE95-E859-E040-BB89AD433043
E12247,ALKALOSIS,8B6C5DD5-D15F-4885-E040-BB89AD4353DF
C110990,ALL OF THE TIME,E5A5650A-6C26-A639-E040-BB89AD432D08
E11248,ALLERGIC REACTION,8B8707AD-6BC9-83F4-E040-BB89AD437E4A
E13303,ALLERGIC RHINITIS,8AA9B42C-5604-F841-E040-BB89AD437B33
C119986,ALMOST ALL OF THE TIME,0C2EFF23-A4B8-667C-E050-BB89AD432C57
C19936,"ALTERNATIVE MEDICINE, DIRECT",8E06DFCA-033D-3663-E040-BB89AD4323BD
C129348,ALWAYS OR ALMOST ALWAYS,3E9E3F56-0703-4FE4-E053-F662850A599D
C32098,ANTERIOR MEDIASTINUM,07472A5E-FE4B-B276-E050-BB89AD431BF5
C118796,ANTI-CD3 ANTIBODY,083D4EDE-68B5-1159-E050-BB89AD4331B5
C17675,ANTIGEN KI-67,F37D0428-B606-6787-E034-0003BA3F9857
C94631,ANTIRETROVIRAL THERAPY,05736430-43F2-C7C3-E050-BB89AD434E79
C16236,ANTISENSE THERAPY,186872B3-019B-23F5-E044-0003BA3F9857
C78597,APL DIFFERENTIATION SYNDROME,74419E3D-8A4D-7FAC-E040-BB89AD434C1B
C43374,APOCRINE CELL,6815D539-E835-D84D-E040-BB89AD43176C
C64774,AREA UNDER CURVE,40A67477-8B02-45C1-E044-0003BA3F9857
C50464,ARTHRALGIA,15926B17-D2B3-2422-E044-0003BA3F9857
C121126,AS EXPECTED,1212163D-1987-C496-E050-BB89AD436E75
C64499,AS NECESSARY,4B8E281C-F76A-621A-E044-0003BA3F9857
C41260,ASIAN,FE0FD98C-B593-595D-E034-0003BA3F9857
C286,ASPARAGINASE,B8DF6309-A0D4-1E33-E040-BB89AD43040B
C77180,ASPERGILLUS,5C109FA8-1D73-5A8A-E044-0003BA3F9857
C28245,ASPIRATION ADVERSE EVENT,F37D0428-E696-6787-E034-0003BA3F9857
C287,ASPIRIN,F37D0428-B6D2-6787-E034-0003BA3F9857
C60781,ASTROCYTOMA,628169CF-839E-F4D3-E040-BB89AD433D78
C50466,ATRIAL FIBRILLATION,18791C00-9F18-4E01-E044-0003BA3F9857
C3519,"ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE",F37D0428-DBBA-6787-E034-0003BA3F9857
C38036,AUDIOMETRIC TEST,3CD92395-4761-4FA8-E044-0003BA3F9857
C85866,AUTOSOMAL RECESSIVE DISORDER,7FBE7AAE-64A7-1C10-E040-BB89AD43016D
C62017,AV BLOCK SECOND DEGREE MOBITZ TYPE I,7458E815-9437-DD76-E040-BB89AD43104A
C62018,AV BLOCK SECOND DEGREE MOBITZ TYPE II,7458E815-9480-DD76-E040-BB89AD43104A
C12904,AXILLARY LYMPH NODE,F37D0428-B5DE-6787-E034-0003BA3F9857
C28844,AZITHROMYCIN,0C625C4B-2C4C-27E6-E044-0003BA3F9857
C8644,B ACUTE LYMPHOBLASTIC LEUKEMIA,27F3CBD2-04DC-469E-E044-0003BA3F9857
C38896,B-LYMPHOCYTE ANTIGEN CD20,51856E82-CA60-2640-E044-0003BA3F9857
C73261,BENDAMUSTINE,916763D9-5D2F-609F-E040-BB89AD437013
C16333,BENIN,12D3F61A-E51F-1D6A-E044-0003BA3F9857
C16342,BIOMARKER,F37D0428-B5BA-6787-E034-0003BA3F9857
C16352,BLACK OR AFRICAN AMERICAN,FE0FD98C-B58E-595D-E034-0003BA3F9857
C61213,BLADDER CANCER PT3 TNM FINDING V6 AND V7,B7474902-F1D7-3AC9-E040-BB89AD434205
C9110,"BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE",38DBE882-E436-674F-E044-0003BA3F9857
C7203,BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM,F37D0428-DBDA-6787-E034-0003BA3F9857
C12679,BLOOD VESSEL,F37D0428-B9AE-6787-E034-0003BA3F9857
C13041,BODY,F37D0428-BBA6-6787-E034-0003BA3F9857
C16359,"BOLIVIA, PLURINATIONAL STATE OF",F37D0428-E11A-6787-E034-0003BA3F9857
C12431,BONE MARROW,F37D0428-BB9E-6787-E034-0003BA3F9857
C15644,BONE MARROW ASPIRATION,3C66B052-4132-0F1C-E044-0003BA3F9857
C15193,BONE MARROW BIOPSY,F37D0428-DF0E-6787-E034-0003BA3F9857
C15194,BONE MARROW TRANSPLANTATION,F37D0428-BBAA-6787-E034-0003BA3F9857
C61545,BONE MINERAL DENSITY TEST,18EEC803-912D-04BF-E044-0003BA3F9857
C14157,BORDERLINE,20417B69-9479-1F41-E044-0003BA3F9857
C7983,BORDERLINE OVARIAN ENDOMETRIOID TUMOR,A67BAD06-70D4-ACFF-E040-BB89AD437FAC
C4783,BORDERLINE OVARIAN EPITHELIAL TUMOR,0F8C8F0D-8A65-02A0-E050-BB89AD430E17
C7281,BORDERLINE OVARIAN MIXED EPITHELIAL TUMOR,A67BAD06-6FD9-ACFF-E040-BB89AD437FAC
C40036,BORDERLINE OVARIAN MUCINOUS TUMOR,A67BAD06-6FB3-ACFF-E040-BB89AD437FAC
C40027,BORDERLINE OVARIAN SEROUS TUMOR WITH MICROINVASION,A67BAD06-6FFF-ACFF-E040-BB89AD437FAC
C49636,BOTH,10B36BC0-C2C4-695F-E044-0003BA3F9857
C19635,BRCA1 GENE MUTATION,AE9028DE-586E-8BC2-E040-BB89AD4348AC
C19636,BRCA2 GENE MUTATION,AE9028DE-5894-8BC2-E040-BB89AD4348AC
C40360,BREAST ADENOCARCINOMA WITH SPINDLE CELL METAPLASIA,06CB4BCA-3156-23F2-E044-0003BA3F9857
C3484,BREAST ADENOSIS,A6CA5E9E-1D11-D7DA-E040-BB89AD432E47
C73347,BREAST CANCER CN0 TNM FINDING V6 AND V7,BB9ECD53-143D-8642-E040-BB89AD43080C
C73350,BREAST CANCER CN2A TNM FINDING V6 AND V7,BB9ECD53-13CB-8642-E040-BB89AD43080C
C88369,BREAST CANCER CN2B TNM FINDING V7,BB9ECD53-13A5-8642-E040-BB89AD43080C
C73353,BREAST CANCER CN3A TNM FINDING V6 AND V7,BB9ECD53-1359-8642-E040-BB89AD43080C
C73354,BREAST CANCER CN3B TNM FINDING V6 AND V7,BB9ECD53-1333-8642-E040-BB89AD43080C
C73346,BREAST CANCER CNX TNM FINDING V6 AND V7,BB9ECD53-1463-8642-E040-BB89AD43080C
C48998,BREAST CANCER PN1A TNM FINDING V6 AND V7,6FCB3DDF-8375-F24C-E040-BB89AD432006
C48999,BREAST CANCER PN1B TNM FINDING V6,6FCB3DDF-834F-F24C-E040-BB89AD432006
C49000,BREAST CANCER PN1C TNM FINDING V6,6FCB3DDF-8329-F24C-E040-BB89AD432006
C88353,BREAST CANCER PN1MI TNM FINDING V7,D4117659-9E59-8B68-E040-BB89AD435F51
C49007,BREAST CANCER PN3C TNM FINDING V6 AND V7,6FCB1360-FDBE-8A77-E040-BB89AD431272
C4872,BREAST CARCINOMA,11C95199-1599-5C1E-E044-0003BA3F9857
C15280,BREAST CONSERVATION TREATMENT,3A7E6D27-EC45-2903-E044-0003BA3F9857
C3744,BREAST FIBROADENOMA,F37D0428-E4AA-6787-E034-0003BA3F9857
C84603,BUNDLE BRANCH BLOCK BY ECG FINDING,9F52E161-B4F2-C614-E040-BB89AD4377D5
C7400,BURKITT LEUKEMIA,27F6CF08-5950-36DF-E044-0003BA3F9857
C121737,CAN DO WITH A LITTLE DIFFICULTY,1546B3B7-644A-CDEB-E050-BB89AD434043
C121740,CAN DO WITH MUCH DIFFICULTY,1546B3B7-6494-CDEB-E050-BB89AD434043
C121739,CAN DO WITH SOME DIFFICULTY,1546B3B7-646F-CDEB-E050-BB89AD434043
C121736,CAN DO WITHOUT ANY DIFFICULTY,1546B3B7-6425-CDEB-E050-BB89AD434043
C77173,CANDIDA KRUSEI,5C109FA8-1E8C-5A8A-E044-0003BA3F9857
C62578,CAPILLARY LEAK SYNDROME,56172F89-7754-66E4-E044-0003BA3F9857
C64696,CAPLET DOSING UNIT,448035F0-BBDB-6C07-E044-0003BA3F9857
C25158,CAPSULE DOSAGE FORM,F37D0428-CE16-6787-E034-0003BA3F9857
C1282,CARBOPLATIN,0303DF01-F41D-15EC-E044-0003BA3F9857
C2916,CARCINOMA,F37D0428-BC06-6787-E034-0003BA3F9857
C2917,CARCINOMA IN SITU,F37D0428-BC12-6787-E034-0003BA3F9857
C34448,CARCINOSARCOMA,F37D0428-E4A6-6787-E034-0003BA3F9857
C12686,CARDIOVASCULAR SYSTEM,F37D0429-4224-6787-E034-0003BA3F9857
C26554,CASP1 GENE,77039323-3A1D-00CF-E040-BB89AD43795B
C42784,CASPASE ACTIVATION,2BA592D6-D048-6ED2-E044-0003BA3F9857
C25372,CATEGORY,D6935A5D-9CE5-4A15-E040-BB89AD435626
C18364,CBL GENE,F4F7B19C-C76D-BB5D-E040-BB89AD4325AD
C118495,CD45RO,222558F6-D19A-9AE6-E050-BB89AD430E73
C104113,CEACAM1 GENE,E387D3D6-6F02-7024-E040-BB89AD433EAF
C17387,CELLULAR TUMOR ANTIGEN P53,36934AAA-BFBD-3C59-E044-0003BA3F9857
C41151,CELSIUS SCALE,F37D0428-B95E-6787-E034-0003BA3F9857
C12438,CENTRAL NERVOUS SYSTEM,F37D0428-B89A-6787-E034-0003BA3F9857
C12300,CENTRAL PORTION OF THE BREAST,06CB4BCA-313A-23F2-E044-0003BA3F9857
C68637,CERTIFICATE,412F97A9-A14A-1B3C-E044-0003BA3F9857
C4029,CERVICAL ADENOCARCINOMA,0F886EE6-BA65-DB60-E050-BB89AD4356E3
C89529,CERVICAL CANCER PT1A2 TNM FINDING V7,9299B94C-420E-BA08-E040-BB89AD430CAF
C89533,CERVICAL CANCER PT1B1 TNM FINDING V7,9299B94C-425A-BA08-E040-BB89AD430CAF
C89534,CERVICAL CANCER PT1B2 TNM FINDING V7,9299B94C-4280-BA08-E040-BB89AD430CAF
C89537,CERVICAL CANCER PT2A1 TNM FINDING V7,9299B94C-42F2-BA08-E040-BB89AD430CAF
C89538,CERVICAL CANCER PT2A2 TNM FINDING V7,9299B94C-4318-BA08-E040-BB89AD430CAF
C4028,"CERVICAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED",C47BC307-67FF-000B-E040-BB89AD43320C
C12311,CERVIX UTERI,F37D0428-EE28-6787-E034-0003BA3F9857
C15632,CHEMOTHERAPY,F37D0428-BBFA-6787-E034-0003BA3F9857
C38103,CHEST RADIOGRAPHY,1A0C42CB-346E-090B-E044-0003BA3F9857
LA20738-3,CHILD (1-12 YEARS),2822FF80-9A85-0EAB-E050-BB89AD4370A6
C4436,CHOLANGIOCARCINOMA,96D7AA2D-09AF-EB1F-E040-BB89AD436E93
C61674,CHOLINE,C90A9C35-C4D7-34CE-E040-BB89AD436E30
C4563,"CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED",49BDA45E-ED4D-65D3-E044-0003BA3F9857
C4981,CHRONIC GRAFT VERSUS HOST DISEASE,F37D0428-B69E-6787-E034-0003BA3F9857
C3163,CHRONIC LYMPHOCYTIC LEUKEMIA,F37D0428-BC0E-6787-E034-0003BA3F9857
C3174,"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE",F37D0428-BC0A-6787-E034-0003BA3F9857
C3199,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,F37D0428-B8E2-6787-E034-0003BA3F9857
C4033,CLEAR CELL RENAL CELL CARCINOMA,21AE5D20-FA3C-1E4D-E044-0003BA3F9857
C129412,CLOSTRIDIUM CLUSTER IV,4301FCFA-72FA-5668-E053-F662850A0382
C9874,CMF REGIMEN,B9065DDB-F5D7-EA21-E040-BB89AD43659B
C106167,COAHUILA,E9E4BB67-8FF3-D876-E040-BB89AD43090E
C72729,COLISTIMETHATE,8496CD40-BEBE-38E5-E040-BB89AD431EE9
C60844,COLORECTAL CANCER PT1 TNM FINDING V6 AND V7,622DC528-033B-C782-E040-BB89AD4370E6
C60845,COLORECTAL CANCER PT2 TNM FINDING V6 AND V7,622DC528-0315-C782-E040-BB89AD4370E6
C16457,COMORBIDITY,27A68410-2F53-1DDF-E044-0003BA3F9857
C70611,COMPLEMENT HEMOLYTIC ACTIVITY ASSAY,3C610493-D4D1-1A80-E044-0003BA3F9857
C15178,COMPLEMENTARY AND ALTERNATIVE MEDICINE,F37D0428-BBE6-6787-E034-0003BA3F9857
C50501,COMPLETE ATRIOVENTRICULAR BLOCK,742DD56B-1420-A7E6-E040-BB89AD43063D
C4870,COMPLETE REMISSION,F37D0428-BC2E-6787-E034-0003BA3F9857
C17204,COMPUTED TOMOGRAPHY,F37D0428-B7BA-6787-E034-0003BA3F9857
C2849,CONGENITAL ABNORMALITY,7E1461A5-7AB0-590A-E040-BB89AD436E02
C61236,CONGENITAL PURE RED CELL APLASIA,28821862-CF49-1939-E044-0003BA3F9857
C48271,CONSENT WITHDRAWN,CD36FBA4-3A58-05B5-E040-BB89AD431ECE
C40207,COPY NUMBER POLYMORPHISM,E4117F95-F325-44B1-E040-BB89AD432ED4
C15680,CORE BIOPSY,F37D0428-B83A-6787-E034-0003BA3F9857
C28944,CREAM DOSAGE FORM,F37D0428-E5D2-6787-E034-0003BA3F9857
C48863,CUTANEOUS MELANOMA PN3 TNM FINDING V6 AND V7,6FCB1360-FCB4-8A77-E040-BB89AD431272
C48845,CUTANEOUS MELANOMA PT2 TNM FINDING V6 AND V7,621FBE50-522C-B33F-E040-BB89AD433DE7
C48846,CUTANEOUS MELANOMA PT2A TNM FINDING V6 AND V7,622D384E-D0FC-A22D-E040-BB89AD4370AF
C48847,CUTANEOUS MELANOMA PT2B TNM FINDING V6 AND V7,622D384E-D0D6-A22D-E040-BB89AD4370AF
C48848,CUTANEOUS MELANOMA PT3 TNM FINDING V6 AND V7,622D384E-D0B0-A22D-E040-BB89AD4370AF
C48849,CUTANEOUS MELANOMA PT3A TNM FINDING V6 AND V7,622D384E-D08A-A22D-E040-BB89AD4370AF
C48850,CUTANEOUS MELANOMA PT3B TNM FINDING V6 AND V7,622D384E-D16F-A22D-E040-BB89AD4370AF
C48851,CUTANEOUS MELANOMA PT4 TNM FINDING V6 AND V7,622D384E-D149-A22D-E040-BB89AD4370AF
C48852,CUTANEOUS MELANOMA PT4A TNM FINDING V6 AND V7,622D384E-D123-A22D-E040-BB89AD4370AF
C48853,CUTANEOUS MELANOMA PT4B TNM FINDING V6 AND V7,622D384E-D1BC-A22D-E040-BB89AD4370AF
C48841,CUTANEOUS MELANOMA PTIS TNM FINDING V6 AND V7,621F52AA-F79C-C9E5-E040-BB89AD43707D
C408,CYTARABINE,443FAAF5-4134-370B-E044-0003BA3F9857
C129886,CYTOKINE EXPRESSION PROFILE,48F89F05-739D-1865-E053-F662850A65DE
C14196,CYTOMEGALOVIRUS,F37D0428-CABE-6787-E034-0003BA3F9857
C82386,DABRAFENIB,9A4E41E5-A33B-57BF-E040-BB89AD4327A8
C25473,DAILY,F37D0428-D066-6787-E034-0003BA3F9857
C48871,DATE DATA TYPE,7AB62440-7698-4783-E040-BB89AD437BC5
C48275,DEATH RELATED TO ADVERSE EVENT,0DDF0D1A-22F6-6548-E044-0003BA3F9857
C9182,DEEP FIBROMATOSIS/DESMOID TUMOR,A6CA5E9E-1C17-D7DA-E040-BB89AD432E47
C53260,DEFINITELY RELATED TO INTERVENTION,90F18618-F96C-4134-E040-BB89AD4326D2
C44277,DEGREE FAHRENHEIT,1346328F-6CD9-1E12-E044-0003BA3F9857
C27260,"DENDRITIC CELL TUMOR, NOT OTHERWISE SPECIFIED",F37D0428-DC22-6787-E034-0003BA3F9857
C38197,DENTAL ROUTE OF ADMINISTRATION,F37D0428-EDC8-6787-E034-0003BA3F9857
C48614,DESMOPLASTIC NEUROTROPIC MELANOMA,06CB4BCA-3127-23F2-E044-0003BA3F9857
C4956,DESMOPLASTIC/NODULAR MEDULLOBLASTOMA,12229D30-D47D-460E-E044-0003BA3F9857
C61702,DESONIDE,A8E4F3E1-0D2D-C4A3-E040-BB89AD436510
C25299,DIASTOLIC BLOOD PRESSURE,F37D0429-4246-6787-E034-0003BA3F9857
C1505,DIETARY SUPPLEMENT,F37D0428-BDF6-6787-E034-0003BA3F9857
C12378,DIGESTIVE SYSTEM,9C907B56-CB7F-5D16-E040-BB89AD435C2A
C29619,DIHYDROTESTOSTERONE,20D039CD-F2F5-5BEA-E044-0003BA3F9857
C50535,DISCOMFORT,728EE47D-6FA5-E9C9-E040-BB89AD431A47
C17747,DISEASE PROGRESSION,F37D0428-BEBE-6787-E034-0003BA3F9857
C50995,DISEASE RESPONSE,0F0AEBD7-9648-60D5-E044-0003BA3F9857
C2992,DISSEMINATED INTRAVASCULAR COAGULATION,F37D0428-BC5A-6787-E034-0003BA3F9857
C106042,DISTANT LYMPH NODE,F446C560-9970-7E7F-E040-BB89AD430D07
C67142,DOES NOT KNOW,32BD33AF-53BE-3D38-E044-0003BA3F9857
C53262,DOMESTIC PARTNERSHIP,0E0474D9-8B7C-0507-E044-0003BA3F9857
C457,DOXYCYCLINE,0D052842-75EC-4FD3-E044-0003BA3F9857
C54149,DRUG COMPANY,38DA3245-8F52-3F73-E044-0003BA3F9857
C48789,DUAL X-RAY ABSORPTIOMETRY,704413DB-0322-4987-E040-BB89AD4306C7
C2924,DUCTAL BREAST CARCINOMA IN SITU,F37D0428-BC32-6787-E034-0003BA3F9857
C66933,"DUCTAL BREAST CARCINOMA IN SITU, SOLID TYPE",A6CA5E9E-152E-D7DA-E040-BB89AD432E47
C8419,DYSPLASTIC CEREBELLAR GANGLIOCYTOMA,121EB3EF-034A-3E15-E044-0003BA3F9857
C37944,EAR PAIN,F37D0428-E002-6787-E034-0003BA3F9857
C105722,ECOG PERFORMANCE STATUS 0,ED3424B1-637B-8FA3-E040-BB89AD4336B3
C105723,ECOG PERFORMANCE STATUS 1,ED3424B1-6381-8FA3-E040-BB89AD4336B3
C105725,ECOG PERFORMANCE STATUS 2,ED333C10-5CE6-CD69-E040-BB89AD43493E
C105726,ECOG PERFORMANCE STATUS 3,ED333C10-5CED-CD69-E040-BB89AD43493E
C105727,ECOG PERFORMANCE STATUS 4,ED3424B1-6388-8FA3-E040-BB89AD4336B3
C29027,EFAVIRENZ,03E16831-BAC4-6D9B-E044-0003BA3F9857
C107154,EGFR NP_005219.2:P.G719X,E0391E43-5749-5A36-E040-BB89AD433003
C98515,EGFR NP_005219.2:P.L858R,FF444164-EC24-3A78-E040-BB89AD433300
C98497,EGFR NP_005219.2:P.L861Q,E0285152-B136-3145-E040-BB89AD436AA6
C98503,EGFR NP_005219.2:P.T790M,FF45AD4A-2D9B-CD11-E040-BB89AD435440
C41064,ENDOCRINE,0E0474D9-84FB-0507-E044-0003BA3F9857
C12705,ENDOCRINE SYSTEM,F37D0428-B7E2-6787-E034-0003BA3F9857
C15445,ENDOCRINE THERAPY,F37D0428-B6BE-6787-E034-0003BA3F9857
C27838,ENDOMETRIAL SEROUS ADENOCARCINOMA,AB335DB5-1D1D-F51E-E040-BB89AD437352
C8973,ENDOMETRIOID STROMAL SARCOMA,F37D0428-DC4A-6787-E034-0003BA3F9857
C16546,ENDOSCOPIC PROCEDURE,F37D0428-DC56-6787-E034-0003BA3F9857
C124145,ENDOTHELIAL PROGENITOR CELL,2CFE2618-A7BE-0397-E050-BB89AD431BF2
C4737,ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA,F37D0428-DC5A-6787-E034-0003BA3F9857
C71744,ENZALUTAMIDE,BE5F3C92-EDA2-5858-E040-BB89AD4304B3
C3017,EPENDYMOMA,121C564A-F2BA-3046-E044-0003BA3F9857
C98182,EPITROCHLEAR LYMPH NODE,ADA2A8AB-92AD-8579-E040-BB89AD430C42
C20555,ERCC2 GENE,D6CCC1FC-7FE3-CFA5-E040-BB89AD437B85
C2693,ERLOTINIB HYDROCHLORIDE,691B1103-A54A-3ACB-E040-BB89AD433564
C50693,ESOPHAGEAL PERFORATION,7442C02C-702E-7767-E040-BB89AD432C57
C37227,ETV6-RUNX1 FUSION PROTEIN EXPRESSION,198337A5-20FD-5D74-E044-0003BA3F9857
C61284,EVANS SYNDROME,28C01DC7-5515-0959-E044-0003BA3F9857
C64523,EVERY EIGHT HOURS,B404581B-9D12-EC81-E040-BB89AD433FB4
C64518,EVERY FOUR HOURS,B403E655-FF2F-7182-E040-BB89AD434AC8
C64510,EVERY HOUR,D73FBE1C-63E4-D002-E040-BB89AD436B25
C64525,EVERY OTHER DAY,B404581B-9DAB-EC81-E040-BB89AD433FB4
C64520,EVERY SIX HOURS,B404581B-9CEC-EC81-E040-BB89AD433FB4
C64517,EVERY THREE HOURS,B403E655-FF09-7182-E040-BB89AD434AC8
C64502,EVERY TWELVE HOURS,D73FBE1C-63DE-D002-E040-BB89AD436B25
C64515,EVERY TWENTY-FOUR HOURS,DCC7519F-F89E-67C1-E040-BB89AD4301F8
C64516,EVERY TWO HOURS,95BFEBC2-B1A7-CF2D-E040-BB89AD43014F
C4817,EWING SARCOMA,286E976F-6E8C-3730-E044-0003BA3F9857
C4835,EWING SARCOMA OF BONE,37D5FE1C-A6DE-09FD-E044-0003BA3F9857
C25370,EXCLUSION CRITERIA,F37D0428-CF06-6787-E034-0003BA3F9857
C15751,EXTERNAL BEAM RADIATION THERAPY,F37D0428-B6C2-6787-E034-0003BA3F9857
C3898,EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE,286C5855-1A12-6248-E044-0003BA3F9857
C26769,FACIAL NERVE PALSY,9F52E161-A464-C614-E040-BB89AD4377D5
C60789,FACSIMILE MACHINE,294A9E98-AE07-3E81-E044-0003BA3F9857
C17954,FALKLAND ISLANDS (MALVINAS),12E359EA-7E44-6BD7-E044-0003BA3F9857
C61276,FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,28BCF219-A3B0-13BC-E044-0003BA3F9857
C102560,FAVORABLE,C468948D-C367-7A63-E040-BB89AD431D40
C9595,FEC REGIMEN,4F5148FD-83D0-3F65-E044-0003BA3F9857
C8984,FEMALE REPRODUCTIVE SYSTEM ADENOFIBROMA,F37D0428-DB92-6787-E034-0003BA3F9857
C27020,FEMALE REPRODUCTIVE SYSTEM DISORDER,F38E5F8E-2032-2E48-E034-0003BA3F9857
C1098,FENRETINIDE,F37D0428-E3C2-6787-E034-0003BA3F9857
C19929,FGFR1 GENE,D2F12E4E-D6B2-F3D3-E040-BB89AD433934
C32608,FINGER,0C746E5C-14D9-28AF-E044-0003BA3F9857
C24399,FLT3 GENE,3F527BAA-6EE4-7844-E053-F662850A16FB
C67494,FLT3 INTERNAL TANDEM DUPLICATION,443CA9B6-A80B-1AE7-E044-0003BA3F9857
C67495,FLT3 TYROSINE KINASE DOMAIN POINT MUTATION,443CA9B6-A7E3-1AE7-E044-0003BA3F9857
C964,FLUDEOXYGLUCOSE F-18,1A0C4CDC-1F01-0ACE-E044-0003BA3F9857
C11197,FOLFOX REGIMEN,15931904-EC6B-3603-E044-0003BA3F9857
C20105,FRENCH SOUTHERN AND ANTARCTIC LANDS,77FB43AF-2D85-E42F-E040-BB89AD435BFA
C19066,FRESH TISSUE,F600421C-62B6-0246-E034-0003BA3F9857
C72884,FRIEND,7F6DB60C-325E-A1D2-E040-BB89AD4321B0
C12352,FRONTAL LOBE,F37D0428-E432-6787-E034-0003BA3F9857
C17988,G1/S-SPECIFIC CYCLIN-D1,7F6AE9B9-95B3-559F-E040-BB89AD437EAB
C67135,GENERAL EQUIVALENCY DIPLOMA COMPLETION,32BD3342-4A2D-3CE2-E044-0003BA3F9857
C13348,GENITAL,F37D0428-CA5E-6787-E034-0003BA3F9857
C12810,GENITOURINARY SYSTEM,594ACCA7-614C-720E-E044-0003BA3F9857
C16634,GEORGIA (REPUBLIC),F37D0428-DC86-6787-E034-0003BA3F9857
C4371,GESTATIONAL HYPERTENSION,9F52E161-F5E3-C614-E040-BB89AD4377D5
C28085,GLEASON PATTERN 1,657A7965-9E76-3B8E-E040-BB89AD431958
C28086,GLEASON PATTERN 2,657A7965-9E9B-3B8E-E040-BB89AD431958
C28087,GLEASON PATTERN 3,657A7965-9EC0-3B8E-E040-BB89AD431958
C28088,GLEASON PATTERN 4,657A7965-9EE5-3B8E-E040-BB89AD431958
C28089,GLEASON PATTERN 5,657A7965-9F0A-3B8E-E040-BB89AD431958
C3058,GLIOBLASTOMA,1222CA23-FF38-4BED-E044-0003BA3F9857
C2270,GONADOTROPHIN RELEASING HORMONE,F37D0428-B6BA-6787-E034-0003BA3F9857
C48155,GRAM,1346328F-6CF1-1E12-E044-0003BA3F9857
C67282,GRAM PER SQUARE METER,448035F0-BA91-6C07-E044-0003BA3F9857
C3444,GRANULOMATOSIS WITH POLYANGIITIS,28C01AFF-5E3D-08FB-E044-0003BA3F9857
C3071,GRAVES DISEASE,9F52E161-CF82-C614-E040-BB89AD4377D5
C119987,HAD NO PAIN,0C2D5F69-D8CF-5559-E050-BB89AD436C00
C7402,HAIRY CELL LEUKEMIA,F37D0428-DC8E-6787-E034-0003BA3F9857
C103268,HAND ASSISTED LAPAROSCOPY,0FC5A4E2-2BB4-EAEF-E050-BB89AD432EE0
C124176,HAVE VERY MILD PAIN,2C7A3E15-BD34-6C47-E050-BB89AD437FBD
C42300,"HEAD, EARS, EYES, NOSE AND THROAT",F37D0428-B95A-6787-E034-0003BA3F9857
C3079,HEART DISORDER,10B25E9B-B340-4897-E044-0003BA3F9857
C41165,HEMATOPOIETIC AND LYMPHATIC SYSTEM,9C907B56-CBDB-5D16-E040-BB89AD435C2A
C15431,HEMATOPOIETIC CELL TRANSPLANTATION,33BBDBD7-E7FB-4A2E-E044-0003BA3F9857
C95504,HEMOGLOBIN H DISEASE,9BDC458A-5489-BFF4-E040-BB89AD430CFB
C3097,HEPATITIS B INFECTION,7092C1FC-415B-5FD5-E040-BB89AD431422
C3098,HEPATITIS C INFECTION,F37D0428-E5A6-6787-E034-0003BA3F9857
C8614,HEPATOBILIARY NEOPLASM,28701A35-65FE-579B-E044-0003BA3F9857
C3728,HEPATOBLASTOMA,9F52E161-9100-C614-E040-BB89AD4377D5
C129926,HIDEBOUND,41C3B64C-35FD-078B-E053-F662850A3C97
C67136,HIGH SCHOOL COMPLETION,32BD334D-500B-3CEA-E044-0003BA3F9857
C15651,HIGH-DOSE RATE BRACHYTHERAPY,2626F22D-92F1-7097-E044-0003BA3F9857
C34700,HIRSCHSPRUNG DISEASE,9F52E161-AA58-C614-E040-BB89AD4377D5
C17459,HISPANIC OR LATINO,F37D0428-DE5E-6787-E034-0003BA3F9857
C9294,HISTIOCYTIC AND DENDRITIC CELL NEOPLASM,3B9695F0-3A55-052B-E044-0003BA3F9857
C118485,"HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, A-0301 ALPHA CHAIN",0F4BF15D-54D1-8888-E050-BB89AD434F0A
C62758,HLA-C GENE,3B6DB460-18A3-56CE-E044-0003BA3F9857
C9357,HODGKIN LYMPHOMA,2019ED6E-B58D-6107-E044-0003BA3F9857
C17249,HOLY SEE (VATICAN CITY STATE),12E28E5B-E306-7355-E044-0003BA3F9857
C68605,HOSPITALIZATION OR PROLONGATION OF EXISTING HOSPITALIZATION REQUIRED,BA85A70C-EAD6-7C6C-E040-BB89AD430169
C64593,HOUR OF SLEEP,7086FDDE-24B0-F6F3-E040-BB89AD432209
C14218,HUMAN HERPESVIRUS 6,71855E80-BB6D-E674-E040-BB89AD437920
C14267,HUMAN RESPIRATORY SYNCYTIAL VIRUS,F37D0428-E5BA-6787-E034-0003BA3F9857
C27088,HYPERBILIRUBINEMIA,742DD56B-1652-A7E6-E040-BB89AD43063D
E12310,HYPOALBUMINEMIA,8BC1C923-9677-5F51-E040-BB89AD4331F6
C12246,HYPOPHARYNX,F37D0428-EE58-6787-E034-0003BA3F9857
C81934,IBRUTINIB,A7E1ED79-B5AE-3062-E040-BB89AD431105
C118390,IDH2 GENE MUTATION,0563A626-9877-81B7-E050-BB89AD4370A5
C20135,IGF1R GENE,B906C410-2633-470B-E040-BB89AD4320DF
C17369,IMAGING TECHNIQUE,6E33206B-5A03-2E5D-E040-BB89AD434538
C123154,IMMUNOGLOBULIN HEAVY CHAIN COMPLEMENTARITY DETERMINING REGION 3,1EF08B88-0A3B-350D-E050-BB89AD434618
C16722,IMMUNOHISTOCHEMISTRY,F37D0428-BB52-6787-E034-0003BA3F9857
C25532,INCLUSION CRITERIA,F37D0428-B7DE-6787-E034-0003BA3F9857
C3429,INCONTINENCE,F37D0428-DFF6-6787-E034-0003BA3F9857
LA20737-5,INFANT (>28 DAYS <1 YEAR),2822FF80-9A7E-0EAB-E050-BB89AD4370A6
C26726,INFECTIOUS DISORDER,F37D0428-CD9E-6787-E034-0003BA3F9857
C63705,INFRACLAVICULAR LYMPH NODE,7ACA750B-8E34-C8E0-E040-BB89AD431095
C15388,INFUSION PROCEDURE,F37D0428-CD96-6787-E034-0003BA3F9857
C42946,INJECTABLE DOSAGE FORM,12E7D7B3-C54E-43B3-E044-0003BA3F9857
C71542,INOTUZUMAB OZOGAMICIN,415C998E-DB2A-1F72-E053-F662850A6021
C124258,INTEGRIN ALPHAV/BETA6,26527575-3D71-0B4A-E050-BB89AD433FB6
C12907,INTEGUMENTARY SYSTEM,0DDF0D1A-1E8E-6548-E044-0003BA3F9857
C16135,INTENSITY-MODULATED RADIATION THERAPY,F37D0428-BB46-6787-E034-0003BA3F9857
C20514,INTERLEUKIN-12,0E0474D9-8F98-0507-E044-0003BA3F9857
C32853,INTERNAL MAMMARY LYMPH NODE,1760EDA3-49F2-4161-E044-0003BA3F9857
C15195,INTERNAL RADIATION THERAPY,F37D0428-BBD6-6787-E034-0003BA3F9857
C67374,INTERNATIONAL UNIT OF VITAMIN A,447F7D60-D97D-4B04-E044-0003BA3F9857
C67381,INTERNATIONAL UNIT PER MILLIGRAM OF ALPHA-TOCOPHEROL,447F7D60-D955-4B04-E044-0003BA3F9857
C45908,INTERSEX,F9FD4EEB-23A6-0B27-E034-0003BA3F9857
C124874,INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21,2796F431-2C8E-87F5-E050-BB89AD43578E
C38267,INTRATHECAL ROUTE OF ADMINISTRATION,0DDF0D1A-1FE1-6548-E044-0003BA3F9857
C13346,INTRAVENOUS,0C625C4B-26F3-27E6-E044-0003BA3F9857
C67283,INTRAVENOUS BAG DOSING UNIT,447F7D60-D911-4B04-E044-0003BA3F9857
C37981,INTUBATION PROCEDURE,F37D0428-CAAA-6787-E034-0003BA3F9857
C9245,INVASIVE BREAST CARCINOMA,05DCF1A1-FAC5-3A7D-E044-0003BA3F9857
C4194,"INVASIVE DUCTAL CARCINOMA, NOT OTHERWISE SPECIFIED",06CB4BCA-318A-23F2-E044-0003BA3F9857
C7950,INVASIVE LOBULAR BREAST CARCINOMA,06CB4BCA-3181-23F2-E044-0003BA3F9857
C18430,IRF4 GENE,D5886F79-0405-473B-E040-BB89AD4308CF
C78393,IRON OVERLOAD,745580E8-4270-8FA9-E040-BB89AD433702
C44480,ISLE OF MAN,12E28E5B-E3DB-7355-E044-0003BA3F9857
C603,ISOTRETINOIN,F37D0428-B54E-6787-E034-0003BA3F9857
C37452,IXABEPILONE,91CFFC87-A255-4714-E040-BB89AD4352D5
C67357,JOULE PER SQUARE CENTIMETER,448035F0-B9DC-6C07-E044-0003BA3F9857
C105720,KARNOFSKY PERFORMANCE STATUS 0,E3488D89-A1F9-4E65-E040-BB89AD435EB8
C105707,KARNOFSKY PERFORMANCE STATUS 100,E3488D89-A246-4E65-E040-BB89AD435EB8
C105713,KARNOFSKY PERFORMANCE STATUS 50,E3488D89-A2DD-4E65-E040-BB89AD435EB8
C105712,KARNOFSKY PERFORMANCE STATUS 60,E3488D89-A305-4E65-E040-BB89AD435EB8
C105711,KARNOFSKY PERFORMANCE STATUS 70,E3488D89-A32D-4E65-E040-BB89AD435EB8
C105710,KARNOFSKY PERFORMANCE STATUS 80,E3488D89-A355-4E65-E040-BB89AD435EB8
C105709,KARNOFSKY PERFORMANCE STATUS 90,E3488D89-A37D-4E65-E040-BB89AD435EB8
C63572,KIDNEY CANCER PN0 TNM FINDING V6 AND V7,62AA7F8A-24BB-6A74-E040-BB89AD430E4D
C63571,KIDNEY CANCER PNX TNM FINDING V6 AND V7,62AA7F8A-24E1-6A74-E040-BB89AD430E4D
C63561,KIDNEY CANCER PT0 TNM FINDING V6 AND V7,621DB0C3-CDBB-C46F-E040-BB89AD43648B
C63562,KIDNEY CANCER PT1 TNM FINDING V6 AND V7,621DB0C3-CD95-C46F-E040-BB89AD43648B
C63563,KIDNEY CANCER PT1A TNM FINDING V6 AND V7,621DB0C3-CE08-C46F-E040-BB89AD43648B
C63564,KIDNEY CANCER PT1B TNM FINDING V6 AND V7,621E42C5-5C1F-6878-E040-BB89AD431D17
C63565,KIDNEY CANCER PT2 TNM FINDING V6 AND V7,621E42C5-5BF9-6878-E040-BB89AD431D17
C63560,KIDNEY CANCER PTX TNM FINDING V6 AND V7,621DB0C3-CDE1-C46F-E040-BB89AD43648B
C9384,KIDNEY CARCINOMA,9E241B3C-89F2-11DA-E040-BB89AD437FA3
C3149,KIDNEY DISORDER,2E8DC30B-3ED8-4DD8-E044-0003BA3F9857
C104678,KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR,22175BA5-585A-8825-E050-BB89AD433FE9
C67276,KILOELECTRONVOLT,447F9A72-309B-08CA-E044-0003BA3F9857
C42576,KILOGRAM PER CUBIC METER,3B9AEE0B-DFEA-3784-E044-0003BA3F9857
C67382,KILOUNIT PER KILOGRAM,447F7D60-D816-4B04-E044-0003BA3F9857
C116396,KIT EXON 17 MUTATION,FEBBF8F0-CA3E-BE36-E040-BB89AD432849
C16773,"KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF",12E2A9F9-AFF5-03BB-E044-0003BA3F9857
C16774,"KOREA, REPUBLIC OF",12E2A9F9-AFDD-03BB-E044-0003BA3F9857
C37984,LABORATORY,F37D0428-BEB6-6787-E034-0003BA3F9857
C25294,LABORATORY PROCEDURE,F37D0428-B63A-6787-E034-0003BA3F9857
C1471,LAMIVUDINE,05116195-EB08-7341-E044-0003BA3F9857
C15725,LAPAROSCOPIC SURGERY,05B23066-8E63-1D7B-E044-0003BA3F9857
C4450,LARGE CELL LUNG CARCINOMA,A6B8531E-1762-F891-E040-BB89AD4324F8
C47855,LEFT BREAST,1FB5F70A-FBED-2BD9-E044-0003BA3F9857
C51624,LEFT COLECTOMY,22273662-BD9B-0D02-E044-0003BA3F9857
C2668,LENALIDOMIDE,34857986-EB00-1CED-E044-0003BA3F9857
C3161,LEUKEMIA,F37D0428-BB5E-6787-E034-0003BA3F9857
C12529,LEUKOCYTE,F37D0428-CBEA-6787-E034-0003BA3F9857
C16793,LIBYA,12E2E7E2-7736-0C0F-E044-0003BA3F9857
C84266,LIFE THREATENING ADVERSE EVENT,76133F16-86E9-48DB-E040-BB89AD431ACF
C41337,LIFE THREATENING OR DISABLING ADVERSE EVENT,133A63CA-49CF-49FD-E044-0003BA3F9857
C116096,LIKELY TUMOR COMPLETE METABOLIC RESPONSE BY PET,FC1F85B2-9DA5-AA07-E040-BB89AD434094
C54225,LIMITED RADIATION THERAPY,1866E678-62EE-1023-E044-0003BA3F9857
C120297,LINEAR ARRAY HPV GENOTYPING TEST,0FC886F3-8FF0-34CD-E050-BB89AD4352CE
C42954,LIQUID FILLED CAPSULE DOSAGE FORM,12E86273-9B21-3396-E044-0003BA3F9857
C67388,LITER PER MINUTE,42ED4BDE-E532-3BDF-E044-0003BA3F9857
C7927,LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA,9F52E161-91A0-C614-E040-BB89AD4377D5
C26922,LIVER FAILURE,F37D0428-DFFA-6787-E034-0003BA3F9857
C4018,LOBULAR BREAST CARCINOMA IN SITU,F37D0428-BB62-6787-E034-0003BA3F9857
C99728,LONDON DEAUVILLE CRITERIA POINT SCALE 1,B8DBD3CC-EC30-8EF9-E040-BB89AD433DEA
C99747,LONDON DEAUVILLE CRITERIA POINT SCALE 2,B8DC1A20-575F-940D-E040-BB89AD4318C2
C99748,LONDON DEAUVILLE CRITERIA POINT SCALE 3,B8DC1A20-57D8-940D-E040-BB89AD4318C2
C99749,LONDON DEAUVILLE CRITERIA POINT SCALE 4,B8DC1A20-57B0-940D-E040-BB89AD4318C2
C99750,LONDON DEAUVILLE CRITERIA POINT SCALE 5,B8DC1A20-5788-940D-E040-BB89AD4318C2
C48227,LOST TO FOLLOW-UP,10C2971A-86B2-6425-E044-0003BA3F9857
C29167,LOTION DOSAGE FORM,F37D0428-E5D6-6787-E034-0003BA3F9857
C85254,LOW-DOSE RATE BRACHYTHERAPY,826966D0-097E-50F5-E040-BB89AD431C11
C33020,LOWER LOBE OF THE LEFT LUNG,90C7026C-3220-B383-E040-BB89AD4363DF
C33022,LOWER LOBE OF THE RIGHT LUNG,90C7026C-32BA-B383-E040-BB89AD4363DF
C12302,LOWER-INNER QUADRANT OF THE BREAST,06CB4BCA-3143-23F2-E044-0003BA3F9857
C12304,LOWER-OUTER QUADRANT OF THE BREAST,06CB4BCA-313D-23F2-E044-0003BA3F9857
C34004,LUMBAR REGION,0C746E5C-1679-28AF-E044-0003BA3F9857
C48824,LUMBOSACRAL REGION,BB13282D-2C4E-DBF9-E040-BB89AD43462D
C15755,LUMPECTOMY,F37D0428-DE42-6787-E034-0003BA3F9857
C60979,LUNG CANCER PM1 TNM FINDING V6,6FDAF1EE-444D-07FB-E040-BB89AD435427
C60973,LUNG CANCER PN0 TNM FINDING V6 AND V7,CE14E222-A9AF-2796-E040-BB89AD433C55
C60974,LUNG CANCER PN1 TNM FINDING,6FCB1360-FC42-8A77-E040-BB89AD431272
C88877,LUNG CANCER PN1 TNM FINDING V7,DC229CEB-DA61-AB2A-E040-BB89AD432F0C
C60975,LUNG CANCER PN2 TNM FINDING V6 AND V7,6FCB1360-FC1C-8A77-E040-BB89AD431272
C60976,LUNG CANCER PN3 TNM FINDING V6 AND V7,6FCB1360-FBF6-8A77-E040-BB89AD431272
C60972,LUNG CANCER PNX TNM FINDING V6 AND V7,CE151CCC-5995-0E3F-E040-BB89AD432794
C60966,LUNG CANCER PT0 TNM FINDING V6 AND V7,CE16659A-04C1-1353-E040-BB89AD432781
C60968,LUNG CANCER PT1 TNM FINDING V6,622DC528-046B-C782-E040-BB89AD4370E6
C88868,LUNG CANCER PT1 TNM FINDING V7,DC2235D9-9BFA-EC03-E040-BB89AD435C43
C88869,LUNG CANCER PT1A TNM FINDING V7,DC2235D9-9BD4-EC03-E040-BB89AD435C43
C88870,LUNG CANCER PT1B TNM FINDING V7,DC2235D9-9BAE-EC03-E040-BB89AD435C43
C60969,LUNG CANCER PT2 TNM FINDING V6,622DC528-0445-C782-E040-BB89AD4370E6
C88871,LUNG CANCER PT2 TNM FINDING V7,DC2235D9-9B88-EC03-E040-BB89AD435C43
C88872,LUNG CANCER PT2A TNM FINDING V7,DC2235D9-9B62-EC03-E040-BB89AD435C43
C88873,LUNG CANCER PT2B TNM FINDING V7,DC2235D9-9B3C-EC03-E040-BB89AD435C43
C60970,LUNG CANCER PT3 TNM FINDING V6,622DC528-041F-C782-E040-BB89AD4370E6
C88874,LUNG CANCER PT3 TNM FINDING V7,DC2235D9-9B16-EC03-E040-BB89AD435C43
C60971,LUNG CANCER PT4 TNM FINDING V6,65799075-1049-D993-E040-BB89AD4336F7
C88875,LUNG CANCER PT4 TNM FINDING V7,DC2235D9-9AF0-EC03-E040-BB89AD435C43
C60967,LUNG CANCER PTIS TNM FINDING V6 AND V7,DC2235D9-9C43-EC03-E040-BB89AD435C43
C60965,LUNG CANCER PTX TNM FINDING V6 AND V7,622DC528-0388-C782-E040-BB89AD4370E6
C12745,LYMPH NODE,F37D0428-B572-6787-E034-0003BA3F9857
C3208,LYMPHOMA,F37D0428-BC6A-6787-E034-0003BA3F9857
C3212,LYMPHOPLASMACYTIC LYMPHOMA,286C5855-1972-6248-E044-0003BA3F9857
C17654,"MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF",12E2E7E2-7742-0C0F-E044-0003BA3F9857
C16809,MAGNETIC RESONANCE IMAGING,F37D0428-B8D2-6787-E034-0003BA3F9857
C4627,MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM,2019ED6E-B575-6107-E044-0003BA3F9857
C4890,MALIGNANT DIGESTIVE SYSTEM NEOPLASM,3A947A96-C013-73DC-E044-0003BA3F9857
C4767,MALIGNANT EYE NEOPLASM,9F52E161-9224-C614-E040-BB89AD4377D5
C4913,MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM,0F886EE6-BAD5-DB60-E050-BB89AD4356E3
C4013,MALIGNANT HEAD AND NECK NEOPLASM,0F8A7B21-243F-7895-E050-BB89AD43579D
C2920,MALIGNANT SKIN NEOPLASM,9F52E161-928A-C614-E040-BB89AD4377D5
C7251,MALIGNANT TESTICULAR NEOPLASM,0FDBCC65-13BE-B6F0-E050-BB89AD436073
C3552,MALIGNANT UTERINE NEOPLASM,9F52E161-92CE-C614-E040-BB89AD4377D5
C15354,MAMMOPLASTY,AEA466FF-1063-AA8B-E040-BB89AD431E57
C15277,MASTECTOMY,F37D0428-DCFA-6787-E034-0003BA3F9857
LA20741-7,MATURE ADULT (65-74 YEARS),2822FF80-9A65-0EAB-E050-BB89AD4370A6
C8507,MEASURABLE DISEASE,F37D0428-BF4A-6787-E034-0003BA3F9857
C16830,MEDICAL DEVICE,F9FA7953-85F8-043D-E034-0003BA3F9857
C3222,MEDULLOBLASTOMA,121C27C1-7FB5-28CB-E044-0003BA3F9857
C3224,MELANOMA,F37D0428-BC86-6787-E034-0003BA3F9857
C88695,MELANOMA OF THE CILIARY BODY AND CHOROID PT2D TNM FINDING V7,0461CA29-8D25-9EFC-E050-BB89AD434CBC
C88700,MELANOMA OF THE CILIARY BODY AND CHOROID PT3D TNM FINDING V7,0461CA29-8D00-9EFC-E050-BB89AD434CBC
C88706,MELANOMA OF THE CILIARY BODY AND CHOROID PT4E TNM FINDING V7,0461CA29-8CDB-9EFC-E050-BB89AD434CBC
C6970,MELANOTIC SCHWANNOMA,62A85C92-1294-B23A-E040-BB89AD431D54
C3230,MENINGIOMA,104E246D-122B-4CCE-E044-0003BA3F9857
C3231,MENOPAUSE,F37D0428-CDBE-6787-E034-0003BA3F9857
C4758,METASTATIC MALIGNANT NEOPLASM IN THE LIVER,3978B950-DA9E-3FC6-E044-0003BA3F9857
C106148,MICHOACAN,E9E4BB67-9124-D876-E040-BB89AD43090E
C25300,MICROBIAL CULTURE PROCEDURE,08704E62-EFF5-4DBA-E044-0003BA3F9857
C67311,MICROGRAM PER SQUARE CENTIMETER,A8813952-CD7C-65FF-E040-BB89AD431E43
C48508,MICROMOLE PER LITER,2135907B-0912-67D8-E044-0003BA3F9857
C17881,"MICRONESIA, FEDERATED STATES OF",12E42CA9-D5AC-172E-E044-0003BA3F9857
C36181,MICROPAPILLARY PATTERN,A55A32E7-3442-D7C0-E040-BB89AD437508
C117149,MICRORNA 19B,0A928281-BBDE-E9E8-E050-BB89AD431437
C12286,MIDDLE LOBE OF THE RIGHT LUNG,382201C6-595D-73C2-E044-0003BA3F9857
C2923,MINIMALLY INVASIVE LUNG ADENOCARCINOMA,6281C75A-47D6-A127-E040-BB89AD431A41
C105947,MITOGEN-ACTIVATED PROTEIN KINASE KINASE,DBD1231B-884C-EF8C-E040-BB89AD430574
C1820,MITOMYCIN,9E727F7D-AEDE-154D-E040-BB89AD4315DA
C6878,MIXED ACINAR-NEUROENDOCRINE CARCINOMA OF THE PANCREAS,21EB8750-7BC5-557C-E044-0003BA3F9857
C3517,MIXED CELLULARITY CLASSICAL HODGKIN LYMPHOMA,286D4DB6-4CE9-242A-E044-0003BA3F9857
C6879,MIXED DUCTAL-NEUROENDOCRINE CARCINOMA OF THE PANCREAS,F5483D12-98FC-7230-E034-0003BA3F9857
C4290,MIXED GERM CELL TUMOR,F37D0428-E48E-6787-E034-0003BA3F9857
C16871,"MOLDOVA, REPUBLIC OF",F37D0428-E256-6787-E034-0003BA3F9857
C19966,MOLECULAR FINGERPRINT OF TUMOR,DEFA039E-2431-36BF-E040-BB89AD4357FA
C29268,MOMETASONE FUROATE,0E070B71-9705-1732-E044-0003BA3F9857
C107223,MORE THAN HALF THE DAYS,E141992A-68A2-79DB-E040-BB89AD43560A
C110991,MOST OF THE TIME,E5A5650A-6C4B-A639-E040-BB89AD432D08
C9131,MUCINOUS BREAST CARCINOMA,06CB4BCA-3174-23F2-E044-0003BA3F9857
C38283,MUCOSAL ROUTE OF ADMINISTRATION,0D51E8D8-6C32-387C-E044-0003BA3F9857
C39787,MULTIPLE TUMOR MASSES,31DC44C0-D996-CA58-E050-BB89AD430BE2
C45576,MUTATION ABNORMALITY,9D5F2496-5D1B-3EDC-E040-BB89AD43173D
C7506,MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS,F37D0428-DDAE-6787-E034-0003BA3F9857
C8574,MYELODYSPLASTIC SYNDROME WITH MULTILINEAGE DYSPLASIA,F37D0428-DDB6-6787-E034-0003BA3F9857
C4036,MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS,F37D0428-DDB2-6787-E034-0003BA3F9857
C27262,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM,284500E6-BC6F-45B5-E044-0003BA3F9857
C27780,"MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE",62A6485A-B19E-B656-E040-BB89AD437D5F
C4345,MYELOPROLIFERATIVE NEOPLASM,28454156-4893-574D-E044-0003BA3F9857
C27350,"MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE",F37D0428-DC06-6787-E034-0003BA3F9857
C27781,MYXOID/ROUND CELL LIPOSARCOMA,899A4990-30B0-0CBB-E040-BB89AD434572
C2688,NAB-PACLITAXEL,B9293EA5-1EE4-3D6D-E040-BB89AD4348A8
C33156,NAIL,9F5324E1-CAAF-4BBA-E040-BB89AD4346F8
C103267,NARROW SURGICAL MARGIN,CE4D7D92-1B0B-F7BC-E040-BB89AD437E5E
C38285,NASOGASTRIC ROUTE OF ADMINISTRATION,0DDF0D1A-205C-6548-E044-0003BA3F9857
C12423,NASOPHARYNX,F37D0428-EE74-6787-E034-0003BA3F9857
C41219,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,FE0FD98C-B598-595D-E034-0003BA3F9857
C123275,NEAR COMPLETE RESPONSE OF MULTIPLE MYELOMA OR PLASMA CELL LEUKEMIA,1D23C18F-CA3A-D1E7-E050-BB89AD432950
C16897,NECROTIC PROCESS,F37D0428-BE3E-6787-E034-0003BA3F9857
C38757,NEGATIVE FINDING,F37D0428-CF22-6787-E034-0003BA3F9857
C35681,NEGATIVE TEST RESULT,DB80D3A8-FAAD-C419-E040-BB89AD435340
C15665,NEOADJUVANT THERAPY,F37D0429-42CE-6787-E034-0003BA3F9857
LA20736-7,NEONATE (0-28 DAYS),2822FF80-9A2D-0EAB-E050-BB89AD4370A6
C16836,NEPRILYSIN,EED6D2E8-5EDB-DAE0-E040-BB89AD436A89
C3272,NEUROFIBROMA,62A6E019-5A82-F2F6-E040-BB89AD4350E9
C61258,NEURONAL CEROID LIPOFUSCINOSIS TYPE 3,28BBAD41-DCA0-4B7F-E044-0003BA3F9857
C80520,NEUTROPENIA,7458E815-911A-DD76-E040-BB89AD43104A
C70543,NEVER,4A9F4102-5891-029C-E044-0003BA3F9857
C129350,NEVER OR ALMOST NEVER,3E9D5CAE-9D2E-5BB3-E053-F662850ADD8F
C65108,NEVER SMOKER,515B10FE-F0DF-16AD-E044-0003BA3F9857
C68814,NIVOLUMAB,B2F483BF-2782-ADF2-E040-BB89AD4327EB
C49487,NO,0C746E5C-184A-28AF-E044-0003BA3F9857
C67122,NO FORMAL SCHOOLING,32BD32F1-AB23-3C5A-E044-0003BA3F9857
C131898,NO HEARING PROBLEMS,47A20205-5625-1C43-E053-F662850A0EA3
C53269,NO INFORMATION AVAILABLE,1084B083-8285-21ED-E044-0003BA3F9857
C27045,NODAL ARRHYTHMIA BY ECG FINDING,F37D0428-DFC2-6787-E034-0003BA3F9857
C8863,NODAL MARGINAL ZONE LYMPHOMA,F37D0428-DD52-6787-E034-0003BA3F9857
C3518,NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA,286D2655-C76D-1ADB-E044-0003BA3F9857
C3211,NON-HODGKIN LYMPHOMA,F37D0428-E67A-6787-E034-0003BA3F9857
C2926,NON-SMALL CELL LUNG CARCINOMA,F37D0428-BCD2-6787-E034-0003BA3F9857
C41132,NONE,062AA8FB-F074-0D39-E044-0003BA3F9857
C48660,NOT APPLICABLE,049B5946-2E09-2FE1-E044-0003BA3F9857
C91213,NOT AT ALL,917AA83A-DA99-A8DB-E040-BB89AD43420C
C49484,NOT DONE,12FADB48-7DA2-62CA-E044-0003BA3F9857
C48661,NOT IDENTIFIED,06CB4BCA-3134-23F2-E044-0003BA3F9857
C19594,NOT OTHERWISE SPECIFIED,1B9F7724-65E6-38A5-E044-0003BA3F9857
C43234,NOT STATED,79DA0AE9-18E2-CEA4-E040-BB89AD4337D2
C101887,NOT TESTED,DDDE2D11-CFDD-F8E7-E040-BB89AD431172
C12355,OCCIPITAL LOBE,F37D0428-E43E-6787-E034-0003BA3F9857
C120595,OFTEN,189A2BED-2367-458F-E050-BB89AD4351AE
C42966,OINTMENT DOSAGE FORM,12F8B901-B3B9-1577-E044-0003BA3F9857
C61279,OLIGOARTICULAR STILL DISEASE,28BE172B-37E5-1B07-E044-0003BA3F9857
C3288,OLIGODENDROGLIOMA,62A770F5-59CB-03F5-E040-BB89AD435AD2
C64576,ONCE,7A3D45AF-F52B-62B9-E040-BB89AD430B97
C107212,ONCOPLASTIC PARTIAL MASTECTOMY/LUMPECTOMY WITH ONCOPLASTIC CLOSURE,E0351AD8-E075-C00E-E040-BB89AD4337BA
C66832,ONE,39F56DCD-BC53-0C53-E044-0003BA3F9857
C63523,OPTIMAL CUTTING TEMPERATURE COMPOUND,9F52E0A8-E4BE-4837-E040-BB89AD437666
C12421,ORAL CAVITY,F37D0428-BC92-6787-E034-0003BA3F9857
C38288,ORAL ROUTE OF ADMINISTRATION,0D51E8D8-6C44-387C-E044-0003BA3F9857
C9145,OSTEOSARCOMA,9890B54F-8657-2C65-E040-BB89AD4320B1
C17649,OTHER,F37D0428-BBB6-6787-E034-0003BA3F9857
LA20318-4,OTHER: PLEASE SPECIFY,35CB16D5-E3E3-5D4E-E050-BB89AD4344D5
C4908,OVARIAN CARCINOMA,286E976F-6E41-3730-E044-0003BA3F9857
C60832,OXYGEN SATURATION MEASUREMENT,15CCA091-C0DF-0E0E-E044-0003BA3F9857
C7073,PAGET DISEASE,F37D0428-E4CE-6787-E034-0003BA3F9857
C7951,PAGET DISEASE OF THE BREAST WITH INVASIVE DUCTAL CARCINOMA,06CB4BCA-3184-23F2-E044-0003BA3F9857
C47858,PAGET DISEASE OF THE BREAST WITHOUT INVASIVE CARCINOMA,06CB4BCA-317B-23F2-E044-0003BA3F9857
C15292,PALLIATIVE THERAPY,F37D0428-E51A-6787-E034-0003BA3F9857
C43411,PAPUA NEW GUINEAN,2F590E37-71A7-35CA-E044-0003BA3F9857
C77643,PARAAORTIC LYMPH NODE,90270302-5C50-4370-E040-BB89AD433776
C19597,PARAFFIN EMBEDDED TISSUE,F5FFE785-5ACA-53F7-E034-0003BA3F9857
C34900,PAROXYSMAL ATRIAL TACHYCARDIA,74597246-18BA-6D19-E040-BB89AD431E08
C18058,PARTIAL REMISSION,0D052842-8047-4FD3-E044-0003BA3F9857
C42968,PATCH DOSAGE FORM,12F8B901-B3E9-1577-E044-0003BA3F9857
C48739,PATHOLOGIC TNM FINDING,1F66C01B-C99E-2D8C-E044-0003BA3F9857
C25166,PATIENT DISCHARGE,F37D0428-CEB6-6787-E034-0003BA3F9857
C15722,PATIENT OBSERVATION,F37D0428-CF2E-6787-E034-0003BA3F9857
C1555,PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,0303DF01-F40F-15EC-E044-0003BA3F9857
C12363,PELVIC LYMPH NODE,F37D0428-E52A-6787-E034-0003BA3F9857
C12767,PELVIS,F37D0428-BD06-6787-E034-0003BA3F9857
C28865,PENICILLIN G SODIUM,0D052842-70DA-4FD3-E044-0003BA3F9857
C3316,PENILE FIBROMATOSIS,9F52E161-F1E3-C614-E040-BB89AD4377D5
C732,PENTOSTATIN,049B5946-2D44-2FE1-E044-0003BA3F9857
C67219,PER 100 WHITE BLOOD CELLS,42E8BE52-74B0-6F5A-E044-0003BA3F9857
C48570,PERCENT UNIT,42E8BE52-74D7-6F5A-E044-0003BA3F9857
C4340,"PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED",37D674A7-08B7-57D7-E044-0003BA3F9857
C90169,PERSISTENT DISEASE,986B514C-4ADF-E2CB-E040-BB89AD433A07
C1909,PHARMACOLOGIC SUBSTANCE,07F9D768-37A1-6CA7-E044-0003BA3F9857
C9128,"PHILADELPHIA CHROMOSOME POSITIVE, BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA",28446C9F-B5B8-188F-E044-0003BA3F9857
C104914,PHOTON BEAM RADIATION THERAPY,DCD71A52-9999-6E69-E040-BB89AD430211
C25741,PHYSICIAN,F37D0428-BD2E-6787-E034-0003BA3F9857
C25655,PHYSIOLOGIC RESOLUTION,F37D0428-BEEE-6787-E034-0003BA3F9857
C96271,PIK3CA GENE MUTATION,FF469A4B-6D38-2C10-E040-BB89AD435709
C47671,PIMECROLIMUS,A9207C79-A668-0C05-E040-BB89AD43035E
C6965,PINEAL PARENCHYMAL CELL NEOPLASM,12229D30-D456-460E-E044-0003BA3F9857
C26685,PLACENTAL ABRUPTION,A6D9FB96-377F-EB3C-E040-BB89AD435DB4
C3242,PLASMA CELL MYELOMA,F37D0428-BCC2-6787-E034-0003BA3F9857
C61280,POLYARTICULAR STILL DISEASE,28BE17FA-27F2-1B64-E044-0003BA3F9857
C17003,POLYMERASE CHAIN REACTION,F37D0428-B7EE-6787-E034-0003BA3F9857
C77959,POOR,8A447119-04C8-8CC9-E040-BB89AD4332B2
C14167,POORLY DIFFERENTIATED,F37D0428-DD92-6787-E034-0003BA3F9857
C103847,PORTACAVAL,0DCDB8C1-3EC0-C97F-E050-BB89AD43385C
C38758,POSITIVE FINDING,212068F8-0113-5F65-E044-0003BA3F9857
C17007,POSITRON EMISSION TOMOGRAPHY,F7C5DB4E-AC55-18B5-E034-0003BA3F9857
C53258,POSSIBLY RELATED TO INTERVENTION,90F18618-F991-4134-E040-BB89AD4326D2
C25742,PREGNANCY,F37D0428-BF12-6787-E034-0003BA3F9857
C2862,PRIMARY MYELOFIBROSIS,F37D0428-DBFA-6787-E034-0003BA3F9857
C16168,PRIOR IMMUNOTHERAPY,F37D0428-DE82-6787-E034-0003BA3F9857
C16124,PRIOR THERAPY,F37D0428-B7AE-6787-E034-0003BA3F9857
C70696,PRIVATE HEALTH INSURANCE,C90F7AE7-7089-1411-E040-BB89AD4321A3
C53259,PROBABLY RELATED TO INTERVENTION,90F18618-F9B6-4134-E040-BB89AD4326D2
C79751,PROCEDURE,876FAD38-1801-8CD3-E040-BB89AD432002
C35571,PROGRESSIVE DISEASE,F37D0428-BD0A-6787-E034-0003BA3F9857
C48245,PROSTATE CANCER PN1 TNM FINDING V6 AND V7,6FCB3DDF-826F-F24C-E040-BB89AD432006
C48236,PROSTATE CANCER PT2 TNM FINDING V6 AND V7,621F0959-1BCD-56E5-E040-BB89AD435D85
C48237,PROSTATE CANCER PT2A TNM FINDING V6 AND V7,621F0959-1BA7-56E5-E040-BB89AD435D85
C48238,PROSTATE CANCER PT2B TNM FINDING V6 AND V7,621F0959-1C24-56E5-E040-BB89AD435D85
C48239,PROSTATE CANCER PT2C TNM FINDING V6 AND V7,621F0959-1BFE-56E5-E040-BB89AD435D85
C48240,PROSTATE CANCER PT3 TNM FINDING V6 AND V7,B65A5720-EBF4-9F16-E040-BB89AD435B8C
C89202,PROSTATE CANCER PT3A TNM FINDING V7,B66D065F-17A2-4C96-E040-BB89AD437AF5
C48242,PROSTATE CANCER PT3B TNM FINDING V6 AND V7,621F0959-1C71-56E5-E040-BB89AD435D85
C89203,PROSTATE CANCER PT4 TNM FINDING V7,B65A1D1B-FE97-85BD-E040-BB89AD4365A1
C4863,PROSTATE CARCINOMA,2962D840-ED30-4EC3-E044-0003BA3F9857
C12410,PROSTATE GLAND,F37D0428-BD52-6787-E034-0003BA3F9857
C17525,PROSTATE-SPECIFIC ANTIGEN,F37D0428-BD46-6787-E034-0003BA3F9857
C13314,PROTEASOME,E47E9935-1398-7383-E040-BB89AD433F41
C42651,PROTOCOL,F9FC767D-1D80-4FB7-E034-0003BA3F9857
C66897,PROTON BEAM RADIATION THERAPY,AE05E80B-5828-7FEC-E040-BB89AD4342AB
C48758,PT0 STAGE FINDING,0DD2AADE-B72C-D470-E050-BB89AD4316E0
C48759,PT1 STAGE FINDING,0DD32325-AE0C-6A76-E050-BB89AD4377E6
C48760,PT1A STAGE FINDING,0DD32325-AE15-6A76-E050-BB89AD4377E6
C98187,PULMONARY HILAR LYMPH NODE,ADA2A8AB-92F7-8579-E040-BB89AD430C42
C53991,PUSHING TUMOR MARGIN,5693525F-D2C6-329B-E044-0003BA3F9857
C29973,PUVA PHOTOCHEMOTHERAPY,B9293EA5-1F1D-3D6D-E040-BB89AD4348A8
C106154,QUERETARO,E9E4BB67-9205-D876-E040-BB89AD43090E
C91216,QUITE A BIT,917AA83A-DAFF-A8DB-E040-BB89AD43420C
C9495,RADIAL SCAR/COMPLEX SCLEROSING LESION,F37D0428-E4B6-6787-E034-0003BA3F9857
C15313,RADIATION THERAPY,F37D0428-B836-6787-E034-0003BA3F9857
C15396,RADICAL CYSTECTOMY,E45455FB-6AB5-A38F-E040-BB89AD4358BE
C67446,RADIOACTIVE SEED IMPLANT DOSING UNIT,447CD10B-78D1-6B2D-E044-0003BA3F9857
C38073,RADIONUCLIDE VENTRICULOGRAM SCAN,21E6CE41-5D5E-2256-E044-0003BA3F9857
C15696,RADIOSURGERY,F37D0428-BE2E-6787-E034-0003BA3F9857
C73116,RARELY,4A9F4102-58CD-029C-E044-0003BA3F9857
C50724,RAYNAUD PHENOMENON,4D22ACD9-297B-4DC9-E044-0003BA3F9857
C49498,RECOVERED OR RESOLVED,0D51E8D8-6D32-387C-E044-0003BA3F9857
C54188,RECTOSIGMOID REGION,59DAD5C4-B031-38EB-E044-0003BA3F9857
C38155,RECURRENT DISEASE,F37D0428-BEC6-6787-E034-0003BA3F9857
C124784,REFUSAL TO PARTICIPATE,2653AD7D-EB13-5B33-E050-BB89AD437FF5
C49018,REGIONAL LYMPH NODE,5691AB27-998E-685B-E044-0003BA3F9857
C7541,RETINOBLASTOMA,28701A35-66D3-579B-E044-0003BA3F9857
C18136,REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION,F37D0428-BD7A-6787-E034-0003BA3F9857
C3359,RHABDOMYOSARCOMA,286E976F-6F4B-3730-E044-0003BA3F9857
C47856,RIGHT BREAST,1FB5D83D-C348-263A-E044-0003BA3F9857
C18473,RNA ANALYSIS,2A68A7C2-75C0-0B07-E050-BB89AD436FE8
C17111,RUSSIAN FEDERATION,12E4587B-11C0-1E2A-E044-0003BA3F9857
C17164,"SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA",12E4587B-11ED-1E2A-E044-0003BA3F9857
C83610,SAINT MARTIN (FRENCH PART),8AB98D4E-E9CB-2F02-E040-BB89AD4373B1
C29444,SAQUINAVIR,4B3433CB-B61F-3213-E044-0003BA3F9857
C9118,SARCOMA,F37D0428-BD96-6787-E034-0003BA3F9857
C4189,SECRETORY BREAST CARCINOMA,06CB4BCA-315F-23F2-E044-0003BA3F9857
C91061,SEGMENTECTOMY,8BFEF234-33D1-944B-E040-BB89AD4366C3
C3020,SEIZURE DISORDER,7B198A4F-67A0-7611-E040-BB89AD430A1F
C25200,SELF,F37D0428-DE5A-6787-E034-0003BA3F9857
C47854,SENTINEL LYMPH NODE BIOPSY WITH AXILLARY LYMPH NODE DISSECTION,1FB5EDB1-341D-2A03-E044-0003BA3F9857
C103283,SEPHARDIC JEW,0DCDB8C1-3E58-C97F-E050-BB89AD43385C
C50739,SEROMA,1C13BC8B-E031-6197-E044-0003BA3F9857
C101180,SHOOTING PAIN,BCB15F24-7052-9BFB-E040-BB89AD435917
C25203,SHOULDER,F37D0428-BDA6-6787-E034-0003BA3F9857
C61235,SHWACHMAN-DIAMOND SYNDROME,288217F9-A739-191C-E044-0003BA3F9857
C95539,SICKLE BETA THALASSEMIA,9BC5911C-BDE8-9C43-E040-BB89AD432688
C91838,SIGMOIDECTOMY,90145027-0B48-36E9-E040-BB89AD430E40
C26883,SJOGREN SYNDROME,28BED297-469D-6CF9-E044-0003BA3F9857
C2921,SKIN BASAL CELL CARCINOMA,78AB07DC-B5C5-F05E-E040-BB89AD43180B
C4819,SKIN SQUAMOUS CELL CARCINOMA,0F886EE6-B5E7-DB60-E050-BB89AD4356E3
C50178,SLIDE DEVICE COMPONENT,9F5324E1-CB76-4BBA-E040-BB89AD4346F8
C4917,SMALL CELL LUNG CARCINOMA,F37D0428-BD92-6787-E034-0003BA3F9857
C12386,SMALL INTESTINE,F37D0428-BDB6-6787-E034-0003BA3F9857
C107424,SOCIAL SECURITY DEATH INDEX,E2D1E83A-BCE1-5A81-E040-BB89AD431072
C45300,SOLID,0D052842-818C-4FD3-E044-0003BA3F9857
C9292,SOLID NEOPLASM,286D4DB6-4D10-242A-E044-0003BA3F9857
C17922,SOMATOSTATIN RECEPTOR TYPE 2,0F4BF15D-54F6-8888-E050-BB89AD434F0A
C67137,SOME COLLEGE COMPLETION,3A060804-18CB-6943-E044-0003BA3F9857
C67329,SOURCE DATA NOT AVAILABLE,44539A54-AFE9-15E0-E044-0003BA3F9857
C70719,SPECIMEN AT ROOM TEMPERATURE,E223006A-9D22-AD29-E040-BB89AD4341C4
C33600,SPLENIC HILAR LYMPH NODE,ADA2A8AB-91A6-8579-E040-BB89AD430C42
C34086,SPLENIC TISSUE,D082D24B-7E94-BF67-E040-BB89AD437D17
C101182,STABBING PAIN,BCB15F24-70C1-9BFB-E040-BB89AD435917
C18213,STABLE DISEASE,F37D0428-BD8E-6787-E034-0003BA3F9857
C8932,STAGE 0 COLORECTAL CANCER AJCC V6 AND V7,532DB57E-18D1-4638-E044-0003BA3F9857
C8423,STAGE 0 CUTANEOUS MELANOMA AJCC V6 AND V7,1C537CC5-CB6D-5DB9-E044-0003BA3F9857
C27467,STAGE 0 LUNG CANCER AJCC V6 AND V7,6A85E062-A955-6D6D-E040-BB89AD4362EC
C8513,STAGE I COLORECTAL CANCER AJCC V6 AND V7,532DB57E-18F9-4638-E044-0003BA3F9857
C8258,STAGE I UTERINE SARCOMA AJCC V7,BEFD3837-B66C-9AD8-E040-BB89AD431C21
C87132,STAGE IA UTERINE SARCOMA AJCC V7,BEFD3837-B692-9AD8-E040-BB89AD431C21
C87133,STAGE IB UTERINE SARCOMA AJCC V7,BEFD3837-B6B8-9AD8-E040-BB89AD431C21
C8259,STAGE II UTERINE SARCOMA AJCC V7,BEFD3837-B6DE-9AD8-E040-BB89AD431C21
C87135,STAGE IIIA UTERINE SARCOMA AJCC V7,BEFD3837-B704-9AD8-E040-BB89AD431C21
C87137,STAGE IIIB UTERINE SARCOMA AJCC V7,BEFD3837-B72A-9AD8-E040-BB89AD431C21
C27982,STAGE IIIC,F37D0428-E422-6787-E034-0003BA3F9857
C87138,STAGE IIIC UTERINE SARCOMA AJCC V7,BEFD3837-B750-9AD8-E040-BB89AD431C21
C87140,STAGE IVA UTERINE SARCOMA AJCC V7,BEFD3837-B776-9AD8-E040-BB89AD431C21
C87144,STAGE IVB UTERINE SARCOMA AJCC V7,BEFD3837-B79C-9AD8-E040-BB89AD431C21
C36185,STEATOSIS,A6D9FB96-3596-EB3C-E040-BB89AD435DB4
C15358,STEREOTACTIC RADIOSURGERY,10B2452E-4E63-4541-E044-0003BA3F9857
C61278,STILL DISEASE,28BE1647-DB4C-1AD3-E044-0003BA3F9857
C49151,STILLBIRTH,28C2FB08-3061-1918-E050-BB89AD433444
C89773,SUBCUTANEOUS MASTECTOMY,90145027-0B82-36E9-E040-BB89AD430E40
C6918,SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA,F37D0428-DDF2-6787-E034-0003BA3F9857
C12903,SUPRACLAVICULAR LYMPH NODE,F37D0428-EE6C-6787-E034-0003BA3F9857
C35061,SUPRAVENTRICULAR TACHYCARDIA,743D5322-CDA1-677A-E040-BB89AD434340
C15329,SURGICAL PROCEDURE,F37D0428-B726-6787-E034-0003BA3F9857
C3682,SWEAT GLAND TUBULAR CARCINOMA,F37D0428-DE22-6787-E034-0003BA3F9857
C17182,SYRIAN ARAB REPUBLIC,F37D0428-E32A-6787-E034-0003BA3F9857
C25298,SYSTOLIC BLOOD PRESSURE,F37D0429-41A0-6787-E034-0003BA3F9857
C3183,T ACUTE LYMPHOBLASTIC LEUKEMIA,27F3CBD2-0503-469E-E044-0003BA3F9857
C15699,T-CELL DEPLETION THERAPY,F37D0428-E63A-6787-E034-0003BA3F9857
C129657,T-CELL RECEPTOR PROFILE,41D76FDB-D0E1-3DCA-E053-F662850AEC39
C38903,T-CELL SURFACE GLYCOPROTEIN CD3 ZETA CHAIN,BDE16E13-3002-2EF0-E040-BB89AD430ED9
C16300,T-CELL SURFACE GLYCOPROTEIN CD4,5C0CC8E4-762A-2D77-E044-0003BA3F9857
C48720,T1 STAGE FINDING,1D5A28C7-922E-4238-E044-0003BA3F9857
C42998,TABLET DOSAGE FORM,12F8F3EC-ABBA-1E97-E044-0003BA3F9857
C12271,TAIL OF THE PANCREAS,21206A10-DC2B-5FA5-E044-0003BA3F9857
C855,TAMOXIFEN CITRATE,F37D0428-BE12-6787-E034-0003BA3F9857
C17185,"TANZANIA, UNITED REPUBLIC OF",F37D0428-E35E-6787-E034-0003BA3F9857
C99184,TARTRATE-RESISTANT ACID PHOSPHATASE TYPE 5,BD951960-5376-0DFB-E040-BB89AD432472
C49633,TECHNICAL PROBLEM,10C2971A-8763-6425-E044-0003BA3F9857
C12353,TEMPORAL LOBE,F37D0428-E43A-6787-E034-0003BA3F9857
C16598,THE GAMBIA,F37D0428-E1BE-6787-E034-0003BA3F9857
C555,THERAPEUTIC HYDROCORTISONE,0E0474D9-8F47-0507-E044-0003BA3F9857
C49236,THERAPEUTIC PROCEDURE,1B89860A-B9D4-3798-E044-0003BA3F9857
C35530,THROMBOCYTOSIS,B9A7C16A-0F2C-3D37-E040-BB89AD434466
C12433,THYMUS GLAND,F37D0428-B926-6787-E034-0003BA3F9857
C4815,THYROID GLAND CARCINOMA,2019ED6E-B5C9-6107-E044-0003BA3F9857
C8054,THYROID GLAND FOLLICULAR CARCINOMA,A6B722DF-A824-76E3-E040-BB89AD43333E
C32887,THYROID GLAND ISTHMUS,9AADAEB7-4437-BED0-E040-BB89AD43239D
C3879,THYROID GLAND MEDULLARY CARCINOMA,67B13250-5414-3FB8-E040-BB89AD43483F
C6042,THYROID GLAND ONCOCYTIC ADENOMA,A67A743F-5FCD-D6C3-E040-BB89AD436761
C46068,THYROID GLAND ONCOCYTIC NEOPLASM,0F8A7B21-1F5C-7895-E050-BB89AD43579D
C4035,THYROID GLAND PAPILLARY CARCINOMA,F681E9E5-38EB-E912-E040-BB89AD433874
C17200,TIMOR-LESTE,F37D0428-E34E-6787-E034-0003BA3F9857
C12801,TISSUE,F37D0428-B88E-6787-E034-0003BA3F9857
C25168,TISSUE DONOR,F37D0428-B90A-6787-E034-0003BA3F9857
C16995,TISSUE-TYPE PLASMINOGEN ACTIVATOR,05116195-EB9C-7341-E044-0003BA3F9857
C50779,TORSADES DE POINTES BY ECG FINDING,DD64B7B3-C66F-264E-E040-BB89AD43263A
C38037,TOTAL BILIRUBIN MEASUREMENT,F37D0428-B6B2-6787-E034-0003BA3F9857
C15281,TOTAL MASTECTOMY,F37D0428-BED2-6787-E034-0003BA3F9857
C129396,TRANSCOBALAMIN,2EA23415-229A-8B50-E050-BB89AD4351B0
C116651,TRANSURETHRAL RESECTION OF BLADDER TUMOR,31F2E2E3-4154-2FF4-E050-BB89AD4343FE
C51612,TRANSVERSE COLECTOMY,8810BBAE-1617-FDE3-E040-BB89AD4374BE
C81729,TRISOMY 10,FF469A4B-6E05-2C10-E040-BB89AD435709
C36396,TRISOMY 8,510ADE83-0139-56CD-E044-0003BA3F9857
C17220,TUMOR MARKER,F37D0428-B986-6787-E034-0003BA3F9857
C64496,TWICE DAILY,95BFEBC2-AFDF-CF2D-E040-BB89AD43014F
C48737,TX STAGE FINDING,1D5A28C7-91FE-4238-E044-0003BA3F9857
C27756,TYPICAL ACUTE PROMYELOCYTIC LEUKEMIA,C39C41E5-B836-61D4-E040-BB89AD4306E1
C18030,TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE 11,BC61C31B-42C1-4F48-E040-BB89AD434E83
C101113,U2AF1 GENE,3F3ED907-169F-47E1-E053-F662850AC8DF
C104104,UGT1A7 GENE,D2F1E50A-A541-3628-E040-BB89AD43132C
C17230,ULTRASONOGRAPHY,F37D0428-B97E-6787-E034-0003BA3F9857
C47944,UNCERTAIN,4D3ED582-F0E4-7509-E044-0003BA3F9857
C62432,UNCINATE PROCESS OF PANCREAS,21206A10-DC19-5FA5-E044-0003BA3F9857
C64486,UNCLASSIFIED,82128AAE-65C0-DBAB-E040-BB89AD436C1D
C3692,UNDIFFERENTIATED CARCINOMA,F37D0428-DE2A-6787-E034-0003BA3F9857
C5723,UNDIFFERENTIATED PANCREATIC CARCINOMA WITH OSTEOCLAST-LIKE GIANT CELLS,21EB8750-7B2A-557C-E044-0003BA3F9857
C4247,UNDIFFERENTIATED PLEOMORPHIC SARCOMA,9F52E161-E14F-C614-E040-BB89AD4377D5
C75563,UNEMPLOYMENT,5B0B3589-7810-033A-E044-0003BA3F9857
C62222,UNEVALUABLE,21E94691-346F-556C-E044-0003BA3F9857
C17234,UNITED STATES,12E47B79-CACA-2313-E044-0003BA3F9857
C20112,UNITED STATES MINOR OUTLYING ISLANDS,77FB43AF-3B59-E42F-E040-BB89AD435BFA
C17998,UNKNOWN,F37D0428-B856-6787-E034-0003BA3F9857
C53257,UNLIKELY RELATED TO INTERVENTION,90F18618-F9DB-4134-E040-BB89AD4326D2
C25328,UNRELATED,F37D0428-DF12-6787-E034-0003BA3F9857
C53256,UNRELATED TO INTERVENTION,90F18618-FA00-4134-E040-BB89AD4326D2
C38046,UNSPECIFIED,F752037A-4D2D-36A8-E034-0003BA3F9857
C33021,UPPER LOBE OF THE LEFT LUNG,90C7026C-326D-B383-E040-BB89AD4363DF
C33023,UPPER LOBE OF THE RIGHT LUNG,90C7026C-331B-B383-E040-BB89AD4363DF
C12301,UPPER-INNER QUADRANT OF THE BREAST,06CB4BCA-3146-23F2-E044-0003BA3F9857
C12303,UPPER-OUTER QUADRANT OF THE BREAST,06CB4BCA-3140-23F2-E044-0003BA3F9857
C13309,VAGINAL,F37D0429-41AA-6787-E034-0003BA3F9857
C26924,VENTRICULAR ARRHYTHMIA,F37D0428-CB26-6787-E034-0003BA3F9857
C43462,VERMONT,01D4D496-BA18-3A9F-E044-0003BA3F9857
C70638,VERY GOOD PARTIAL RESPONSE OF MULTIPLE MYELOMA OR PLASMA CELL LEUKEMIA,3D3B8450-425B-6519-E044-0003BA3F9857
C91217,VERY MUCH,917AA83A-DB21-A8DB-E040-BB89AD43420C
C91245,VERY OFTEN,974E24B4-B15A-187D-E040-BB89AD4353EF
C17252,VIET NAM,F37D0428-E376-6787-E034-0003BA3F9857
C26749,VIP-PRODUCING NEUROENDOCRINE TUMOR,9F52E162-0921-C614-E040-BB89AD4377D5
C67350,VIRAL PARTICLE UNIT,44852E0B-70CB-30CC-E044-0003BA3F9857
C17653,"VIRGIN ISLANDS, BRITISH",12D3F61A-E5E2-1D6A-E044-0003BA3F9857
C17255,"VIRGIN ISLANDS, U.S.",12E47B79-CB4B-2313-E044-0003BA3F9857
C67141,VOCATIONAL PROGRAM COMPLETION,32BD335F-677A-3CFA-E044-0003BA3F9857
C80307,WALDENSTROM MACROGLOBULINEMIA,832F1E62-11DF-273F-E040-BB89AD432C6A
C73468,WALDEYER'S TONSILLAR RING,D082D24B-7D99-BF67-E040-BB89AD437D17
C17259,WALLIS AND FUTUNA,12E47B79-CB63-2313-E044-0003BA3F9857
C67069,WEEKLY,6940BC12-3AC1-A337-E040-BB89AD437FD0
C16357,WESTERN BLOTTING,013786F9-7A80-629F-E044-0003BA3F9857
C41261,WHITE,FE0FD98C-B59D-595D-E034-0003BA3F9857
C41067,WHOLE BLOOD,F87BDF80-310F-312E-E034-0003BA3F9857
C16187,WHOLE-BRAIN RADIOTHERAPY,10B2452E-4E7B-4541-E044-0003BA3F9857
C3267,WILMS TUMOR,28701A35-66B8-579B-E044-0003BA3F9857
C3718,WILMS TUMOR-ANIRIDIA-GENITOURINARY ANOMALIES-MENTAL RETARDATION SYNDROME,9F52E162-0B67-C614-E040-BB89AD4377D5
C49634,WITHDRAWAL BY SUBJECT,10C2971A-877B-6425-E044-0003BA3F9857
C50863,WOUND DEHISCENCE,1C13BC8B-E049-6197-E044-0003BA3F9857
C33894,WRIST JOINT,992E297C-92E5-7D0D-E040-BB89AD4378FE
C26917,XEROSTOMIA,F37D0428-CA26-6787-E034-0003BA3F9857
C49488,YES,0C746E5C-184F-28AF-E044-0003BA3F9857
C1699,ZOLEDRONIC ACID,0303DF01-F4EC-15EC-E044-0003BA3F9857
C19998,ZUBROD PERFORMANCE STATUS 0,D40B8596-31F9-5022-E040-BB89AD433654
C19999,ZUBROD PERFORMANCE STATUS 1,D40B8596-321F-5022-E040-BB89AD433654
C17846,ZUBROD PERFORMANCE STATUS 2,D40B8596-3244-5022-E040-BB89AD433654
